



Q & M DENTAL GROUP (SINGAPORE) LIMITED
(Company Registration Number 200800507R)
(Incorporated in the Republic of Singapore)

PRICING OF S\$130,000,000 3.95 PER CENT NOTES DUE 2028 TO BE ISSUED BY Q & M DENTAL GROUP (SINGAPORE) LIMITED PURSUANT TO ITS S\$500,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME

The Board of Directors (the “**Board**”) of Q & M Dental Group (Singapore) Limited (the “**Issuer**”) wishes to announce that it has on 3 July 2025 launched and priced its inaugural offering of S\$130,000,000 in aggregate principal amount of 3.95 per cent notes due 2028 comprised in Series 001 (the “**Series 001 Notes**”). The Series 001 Notes will be issued by the Issuer pursuant to its S\$500,000,000 Multicurrency Debt Issuance Programme which was established by the Issuer on 5 December 2017 (the “**Programme**”). The Series 001 Notes are expected to be issued on 10 July 2025.

DBS Bank Ltd., Oversea-Chinese Banking Corporation Limited and United Overseas Bank Limited have been appointed as the joint lead managers of the Series 001 Notes. The Series 001 Notes will be offered to institutional investors (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore (the “**SFA**”)) and accredited investors (as defined in Section 4A of the SFA) only.

The Series 001 Notes will be issued in registered form at an issue price of 100.00 per cent of their principal amount and in denominations of S\$250,000. The Series 001 Notes will bear interest at a fixed rate of 3.95 per cent per annum, payable semi-annually in arrears on 10 January and 10 July in each year, commencing on 10 January 2026. Unless previously redeemed or purchased and cancelled, the Series 001 Notes shall mature on 10 July 2028.

The Series 001 Notes will constitute direct, unconditional, unsubordinated and unsecured obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The net proceeds arising from the issue of the Series 001 Notes (after deducting issue expenses) will be used for general corporate purposes, including financing acquisitions and/or investments (including investments in associated companies), business expansions, refinancing of borrowings and financing of working capital and capital expenditure requirements of the Issuer and/or its subsidiaries.

Application will be made to the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) for the listing and quotation of the Series 001 Notes on the SGX-ST. Such permission will be granted when the Series 001 Notes have been admitted for listing and quotation on the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed, or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 001 Notes on, the SGX-ST are not to be taken as an indication of the merits of

the Issuer, its subsidiaries, its associated companies (if any), the Programme and/or the Series 001 Notes.

Certain directors and/or controlling shareholders of the Issuer and/or persons related to them have been allocated approximately 2.88 per cent of the S\$130,000,000 in aggregate principal amount of Series 001 Notes to be issued.

By Order of the Board
Q & M Dental Group (Singapore) Limited

Ng Sook Hwa
Chief Financial Officer
3 July 2025